| External factors: | Metformin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Colorectal cancer |
| Experiment: | SA-β-gal activity assay//qRT-PCR |
| Description: | In the present study, we found that the metformin/ABT-263 cotreatment induced an obvious cellular senescence in HCT-116 p53+/+ cells, whereas the cotreatment only slightly evoked the cellular senescence in HCT-116 p53?/? cells.In the present study, we found that the metformin/ABT-263 cotreatment induced an obvious cellular senescence in HCT-116 p53+/+ cells, whereas the cotreatment only slightly evoked the cellular senescence in HCT-116 p53?/? cells.ABT-263 significantly increased most of them, which was augmented by metformin in HCT-116 p53+/+ cells. However, these SASP components were unchanged or just mildly increased upon metformin/ABT-263 cotreatment in HCT-116 p53?/? cells. |
| Target gene: | P53 |
| R-EF-Target gene: | -- |
| Official symbol(s): | P53 |
| Target gene experiment: | SA-β-gal activity assay |
| Target gene description: | We found that the metformin/ABT-263 cotreatment induced an obvious cellular senescence in HCT-116 p53+/+ cells, whereas the cotreatment only slightly evoked the cellular senescence in HCT-116 p53?/? cells. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: